This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Merck, Glenmark must face trimmed US antitrust case over Zetia, judge rules

( December 30, 2024, 23:31 GMT | Official Statement) -- MLex Summary: Merck and Glenmark Pharmaceuticals must face Humana’s US claims for damages over purchases of the Merck drug Vytorin in a pay-for-delay suit over generic Zetia, a federal judge ruled. District Judge Brian R. Martinotti did grant dismissal of monopolization claims related to sham patent litigation, finding that Humana failed to meet the heightened standard for pleading actual fraud and therefore can’t claim Merck and Glenmark knowingly and intentionally misrepresented material information to fraudulently obtain the relevant patents. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections